Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2025

12 - 15 Jun 2025

Allianz MiCo, Milano Convention Centre, Milan, Italy

Independent clones in CLL show oligoclonality and early evolution patterns

Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain

10 Jul 2025

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

9 Jul 2025

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Dr Anthony Stein - City of Hope, Duarte, USA

$Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )$

27 Jun 2025

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France

27 Jun 2025

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

27 Jun 2025

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

27 Jun 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

27 Jun 2025

Conferences

EHA 2025

More from ecancer